MCID: SML008
MIFTS: 44

Small Intestine Lymphoma

Categories: Cancer diseases, Immune diseases, Gastrointestinal diseases

Aliases & Classifications for Small Intestine Lymphoma

MalaCards integrated aliases for Small Intestine Lymphoma:

Name: Small Intestine Lymphoma 38 12 15
Small Intestinal Lymphoma 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:13996
NCIt 50 C4007
SNOMED-CT 68 449074003
UMLS 73 C0278805

Summaries for Small Intestine Lymphoma

MalaCards based summary : Small Intestine Lymphoma, also known as small intestinal lymphoma, is related to lymphoplasmacyte-rich meningioma and early yaws. An important gene associated with Small Intestine Lymphoma is CD3E (CD3e Molecule), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Allograft rejection. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include small intestine, b cells and t cells, and related phenotypes are hematopoietic system and immune system

Related Diseases for Small Intestine Lymphoma

Diseases related to Small Intestine Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 lymphoplasmacyte-rich meningioma 10.7 CD79A UCHL1
2 early yaws 10.7 CD22 CD79A
3 panophthalmitis 10.7 CD79A CTSL
4 gastrointestinal allergy 10.6 CD79A ITGAE
5 hyperimmunoglobulin syndrome 10.6 CD40 CD79A
6 tropical sprue 10.6 ALDOB CD3E GIF
7 taeniasis 10.5 CD79A CTSL
8 cd40 ligand deficiency 10.5 CD40 CD79A
9 clonorchiasis 10.5 CD79A CTSL
10 immunodeficiency 18 10.5 CD3E PTPRC
11 liver inflammatory pseudotumor 10.4 PTPRC UCHL1
12 immunodeficiency with hyper-igm, type 1 10.4 CD40 CD79A
13 hodgkin's lymphoma, mixed cellularity 10.4 PTPRC UCHL1
14 transient hypogammaglobulinemia of infancy 10.4 CD19 CD79A
15 congenital hypogammaglobulinemia 10.4 CD19 CD79A
16 testicular infarct 10.3 PTPRC UCHL1
17 rhinoscleroma 10.3 CD19 CD79A
18 gastric small cell carcinoma 10.3 PTPRC UCHL1
19 primary amebic meningoencephalitis 10.3 CD79A CTSL
20 posterior scleritis 10.3 CD19 CD22
21 bladder lymphoma 10.2 CD19 UCHL1
22 lymphoma 10.2
23 plasma protein metabolism disease 10.2 CD19 CD79A
24 sclerosing keratitis 10.2 B2M CD79A
25 gnathomiasis 10.2 CD40 CTSL
26 orthostatic proteinuria 10.1 B2M CD79A
27 diffuse glomerulonephritis 10.0 B2M CD79A
28 danubian endemic familial nephropathy 10.0 B2M CD79A
29 lung lymphoma 10.0 CD19 CD22 CD79A
30 alpha-heavy chain disease 10.0
31 lymphosarcoma 10.0 CD22 CTSL PTPRC
32 alpha chain disease 10.0
33 intestinal disease 10.0
34 amyloid tumor 9.9 B2M CD79A
35 b cell deficiency 9.9 CD19 CD40 CD79A
36 non-secretory myeloma 9.9 B2M CD79A ITGAE
37 non-gestational choriocarcinoma 9.9 B2M MSH6
38 sjogren syndrome 9.8 B2M CD79A SIL1
39 pyelitis 9.8 B2M CD79A
40 lateral medullary syndrome 9.8 CD19 CD22
41 renal tuberculosis 9.7 B2M CTSL
42 heavy chain disease 9.7
43 intestinal tuberculosis 9.7
44 solitary osseous plasmacytoma 9.6 B2M CD19
45 reticulohistiocytic granuloma 9.6 PTPRC UCHL1
46 plasmacytoma 9.6 B2M CD79A PTPRC
47 gamma heavy chain disease 9.5 CD19 CD79A GIF PTPRC
48 monoclonal gammopathy of uncertain significance 9.5 B2M CD19 CD79A
49 combined immunodeficiency, x-linked 9.3 CD19 CD40 CD79A PTPRC
50 common variable immunodeficiency 9.3 CD19 CD40 CD79A

Graphical network of the top 20 diseases related to Small Intestine Lymphoma:



Diseases related to Small Intestine Lymphoma

Symptoms & Phenotypes for Small Intestine Lymphoma

MGI Mouse Phenotypes related to Small Intestine Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 GIF CD19 ITGAE MSH6 CD22 CD3E
2 immune system MP:0005387 10.07 GIF CD19 ITGAE MSH6 CD22 CD3E
3 homeostasis/metabolism MP:0005376 10.02 CD79A B2M GIF CD19 MSH6 CD40
4 liver/biliary system MP:0005370 9.76 B2M GIF CD19 PTPRC UCHL1 CD72
5 neoplasm MP:0002006 9.43 CD79A B2M CD19 MSH6 CD3E PTPRC
6 renal/urinary system MP:0005367 9.1 CD79A CD19 CD40 PTPRC UCHL1 CD72

Drugs & Therapeutics for Small Intestine Lymphoma

Drugs for Small Intestine Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2 Liver Extracts Phase 4,Phase 3,Phase 1,Not Applicable
3 Cola Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
4
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
5
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Ondansetron Approved Phase 3 99614-02-5 4595
8
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
9
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
10
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
12
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
13
Ofloxacin Approved Phase 3 82419-36-1 4583
14
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
15
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2 93-14-1 3516
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17 Orange Approved, Nutraceutical Phase 3
18 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
19 Amoxicillin-Potassium Clavulanate Combination Phase 3
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Antitubercular Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 beta-Lactamase Inhibitors Phase 3
25 Clavulanic Acid Phase 3
26 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
27 Cytochrome P-450 Enzyme Inhibitors Phase 3
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
31 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
32 glucocorticoids Phase 3,Phase 2,Phase 1
33 Hormone Antagonists Phase 3,Phase 2,Phase 1
34 Hormones Phase 3,Phase 2,Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
36 Adjuvants, Anesthesia Phase 3
37 Analgesics Phase 3,Phase 1
38 Analgesics, Opioid Phase 3
39 Anesthetics Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Central Nervous System Depressants Phase 3,Phase 1
43 Narcotics Phase 3
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Anti-Anxiety Agents Phase 3
46 Antiemetics Phase 3,Phase 2,Phase 1
47 Antipruritics Phase 3
48 Antipsychotic Agents Phase 3
49 Autonomic Agents Phase 3,Phase 2,Phase 1
50 Gastrointestinal Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
5 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
6 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
7 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
8 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
9 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
10 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
11 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
12 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
13 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
14 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
15 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
16 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
17 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
18 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
19 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
20 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
21 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine
22 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
23 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
24 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
25 Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
26 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
27 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
28 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Completed NCT00436618 Phase 2 Everolimus
29 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
30 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
31 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
32 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
33 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
34 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
35 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
36 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
37 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
38 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
39 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
40 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
41 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT01261247 Phase 2 panobinostat
42 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
43 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
44 Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Active, not recruiting NCT00416351 Phase 1, Phase 2 clofarabine
45 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
46 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2 lenalidomide
47 MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma Terminated NCT00089076 Phase 1, Phase 2
48 Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
49 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
50 Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma Unknown status NCT00562068 Phase 1 cyclophosphamide;doxorubicin hydrochloride;prednisolone;vincristine sulfate

Search NIH Clinical Center for Small Intestine Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Small Intestine Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Small Intestine Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Small Intestine Lymphoma:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Small Intestine Lymphoma

Anatomical Context for Small Intestine Lymphoma

MalaCards organs/tissues related to Small Intestine Lymphoma:

41
Small Intestine, B Cells, T Cells, Bone, Liver, Bone Marrow, Breast

Publications for Small Intestine Lymphoma

Articles related to Small Intestine Lymphoma:

(show all 13)
# Title Authors Year
1
Comparative study of intestinal tuberculosis and primary small intestinal lymphoma. ( 24764686 )
2014
2
A clinicopathologic study of primary small intestine lymphoma: prognostic significance of mucosa-associated lymphoid tissue-derived lymphoma. ( 10640959 )
2000
3
Immunoproliferative small intestinal disease and primary small intestinal lymphoma: review of literature. ( 9339621 )
1997
4
Clinicopathological features and management of immunoproliferative small intestinal disease and primary small intestinal lymphoma in Pakistan. ( 7674998 )
1995
5
Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease. ( 8021727 )
1994
6
Plasma postheparin diamine oxidase in patients with small intestinal lymphoma. ( 1898707 )
1991
7
Immunoproliferative small intestinal disease and primary small intestinal lymphoma. Relation to alpha chain protein. ( 3928129 )
1985
8
Small intestinal lymphomas and alpha-chain disease. ( 6413104 )
1983
9
Primary small intestinal lymphomas and alpha-heavy-chain disease. A study of 43 cases from a pathology department in Israel. ( 112083 )
1979
10
Primary upper small-intestinal lymphoma and alpha-chain disease. Report of 10 cases emphasizing pathological aspects. ( 418696 )
1978
11
Alpha-chain disease and related small-intestinal lymphoma: a memorandum. ( 829415 )
1976
12
Alpha-chain disease and related small-intestinal lymphoma. Report of a WHO meeting of investigators. ( 829214 )
1976
13
Radiotherapeutic management of small intestinal lymphoma with malabsorption. ( 4569293 )
1973

Variations for Small Intestine Lymphoma

Expression for Small Intestine Lymphoma

Search GEO for disease gene expression data for Small Intestine Lymphoma.

Pathways for Small Intestine Lymphoma

Pathways related to Small Intestine Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 B2M CD19 CD22 CD3E CD40 CD79A
2
Show member pathways
12.65 B2M CD3E CD40 CTSL PTPRC
3 12.39 B2M CD19 CD3E CD79A PTPRC
4
Show member pathways
12.38 CD19 CD22 CD79A PTPRC
5
Show member pathways
12.17 CD19 CD22 CD72 CD79A PTPRC
6
Show member pathways
12.1 CD19 CD22 CD3E CD40 PTPRC
7 11.89 CD22 CD40 PTPRC
8 11.79 B2M CD19 CD22 CD3E CD40
9
Show member pathways
11.75 B2M CD3E PTPRC
10
Show member pathways
11.73 CD19 CD22 CD79A
11 11.72 CD19 CD22 CD3E CD7
12 11.62 CD19 CD22 CD3E CD79A PTPRC
13 11.57 CD7 ITGAE PTPRC
14 11.49 CD19 CD3E ITGAE PTPRC
15 11.42 CD19 CD3E ITGAE
16 11.08 CD19 CD22 CD3E CD40 PTPRC
17 10.59 CD19 CD3E CD40 CD79A PTPRC

GO Terms for Small Intestine Lymphoma

Cellular components related to Small Intestine Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.9 B2M CD19 CD22 CD3E CD40 CD7
2 extracellular exosome GO:0070062 9.61 ALDOB B2M CD19 CD22 CD40 CD7
3 external side of plasma membrane GO:0009897 9.17 B2M CD19 CD3E CD40 CD79A ITGAE

Biological processes related to Small Intestine Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.62 CD19 CD3E CD79A PTPRC
2 adaptive immune response GO:0002250 9.56 CD3E CD7 CD79A CTSL
3 immune system process GO:0002376 9.55 B2M CD3E CD40 CD7 CD79A
4 B cell receptor signaling pathway GO:0050853 9.54 CD19 CD79A PTPRC
5 B cell activation GO:0042113 9.43 CD40 CD79A
6 T cell differentiation in thymus GO:0033077 9.4 B2M CD3E
7 regulation of immune response GO:0050776 9.26 B2M CD19 CD3E CD40
8 B cell proliferation GO:0042100 8.8 CD40 CD79A PTPRC

Sources for Small Intestine Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....